Mizolastine
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB12523 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 100 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | acute intermittent porphyria | KG + DL |
| 2 | psychogenic movement disorders | KG + DL |
| 3 | lingual-facial-buccal dyskinesia | KG + DL |
| 4 | chronic tic disorder | KG + DL |
| 5 | benign shuddering attacks | KG + DL |
| 6 | extrapyramidal and movement disease | KG + DL |
| 7 | primary orthostatic tremor | KG + DL |
| 8 | tremor-nystagmus-duodenal ulcer syndrome | KG + DL |
| 9 | benign paroxysmal tonic upgaze of childhood with ataxia | KG + DL |
| 10 | carbamoyl phosphate synthetase I deficiency disease | KG + DL |
| 11 | juvenile onset Parkinson disease 19A | KG + DL |
| 12 | hyperargininemia | KG + DL |
| 13 | porphyria | KG + DL |
| 14 | hereditary late onset Parkinson disease | KG + DL |
| 15 | miscellaneous movement disorder due to neurodegenerative disease | KG + DL |
| 16 | atypical juvenile parkinsonism | KG + DL |
| 17 | nephrogenic syndrome of inappropriate antidiuresis | KG + DL |
| 18 | parkinsonian-pyramidal syndrome | KG + DL |
| 19 | X-linked parkinsonism-spasticity syndrome | KG + DL |
| 20 | 3-methylcrotonyl-CoA carboxylase 1 deficiency | KG + DL |
| 21 | myelitis | KG + DL |
| 22 | motor stereotypies | KG + DL |
| 23 | hyperammonemic encephalopathy due to carbonic anhydrase VA deficiency | KG + DL |
| 24 | urea cycle disorder | KG + DL |
| 25 | Rasmussen subacute encephalitis | KG + DL |
| 26 | hyperinsulinism-hyperammonemia syndrome | KG + DL |
| 27 | adult-onset citrullinemia type I | KG + DL |
| 28 | acute neonatal citrullinemia type I | KG + DL |
| 29 | erythropoietic uroporphyria associated with myeloid malignancy | KG + DL |
| 30 | Alzheimer disease without neurofibrillary tangles | KG + DL |
| 31 | hemiparkinsonism-hemiatrophy syndrome | KG + DL |
| 32 | open-angle glaucoma | KG + DL |
| 33 | allergic urticaria | KG + DL |
| 34 | hereditary photodermatosis | KG + DL |
| 35 | transaldolase deficiency | KG + DL |
| 36 | primary hereditary glaucoma | KG + DL |
| 37 | fructose-1,6-bisphosphatase deficiency | KG + DL |
| 38 | citrullinemia, type II, adult-onset | KG + DL |
| 39 | early-onset parkinsonism-intellectual disability syndrome | KG + DL |
| 40 | hypertrichosis (disease) | KG + DL |
| 41 | intermittent explosive disorder | KG + DL |
| 42 | PLA2G6-associated neurodegeneration | KG + DL |
| 43 | drug-induced dyskinesia | KG + DL |
| 44 | syndrome with a Dandy-Walker malformation as major feature | KG + DL |
| 45 | malformation syndrome with odontal and/or periodontal component | KG + DL |
| 46 | isolated genetic hair shaft abnormality | KG + DL |
| 47 | subarachnoid hemorrhage (disease) | KG + DL |
| 48 | multiple system atrophy | KG + DL |
| 49 | porphyria due to ALA dehydratase deficiency | KG + DL |
| 50 | progressive supranuclear palsy-corticobasal syndrome | KG + DL |
(Showing top 50 of 100 predictions)
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.